← Eichor
Study identifier: NCT06266299 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

Condition: Advanced Solid Tumor · Metastatic Solid Tumor · Gastric Adenocarcinoma  ·  Sponsor: Kyowa Kirin Co., Ltd.

PhasePhase 1
Planned participants101
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary objective is to assess the safety and tolerability of KK2269. In Part 2, only participants with gastric adenocarcinoma, GEJ adenocarcinoma, esophageal adenocarcinoma, or NSCLC who have experienced at least one systemic therapy will be enrolled. In Part 2, the primary objective is to assess the safety and tolerability of KK2269 in combination with docetaxel and to determine the recommended dose(s) and dose interval(s) of KK2269 in combination with docetaxel for subsequent studies. In both Part 1 and Part 2, participants who refuse to undergo standard therapy are also eligible.

This description comes directly from the study's public registry record.

Talk to the study team

Kyowa Kirin Co., Ltd.  ·  +81-3-5205-7200  ·  clinical.info.jp@kyowakirin.com

Kyowa Kirin, Inc.  ·  609-919-1100  ·  kkd.clintrial.82@kyowakirin.com

Always discuss trial participation with your own doctor first.

Locations (11)

Mayo Clinic ArizonaScottsdale, Arizona, United StatesRecruiting
City Of Hope National Medical CenterDuarte, California, United StatesRecruiting
Hoag Memorial Hospital PresbyterianNewport Beach, California, United StatesRecruiting
Mayo Clinic JacksonvilleJacksonville, Florida, United StatesRecruiting
Washington UniversitySt Louis, Missouri, United StatesRecruiting
The University of Texas Southwestern Medical CenterDallas, Texas, United StatesRecruiting
University of WashingtonSeattle, Washington, United StatesRecruiting
Aichi Cancer CenterNagoya, Aichi-ken, JapanRecruiting
National Cancer Center Hospital EastKashiwa, Chiba, JapanRecruiting
National Cancer Center HospitalChuo-ku, Tokyo, JapanRecruiting
Cancer Institute Hospital of JFCRKoto-Ku, Tokyo, JapanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06266299